Andrew Keller, MD
Advanced Heart Failure and Transplant Cardiology · Culpeper, VANPI 1205928876
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Akcea Therapeutics, Inc. at 57.5% of the total. Reporting peaked in 2019 at $3,641 and has fallen 99.2% since, to $29 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in VA, where the typical reported total is $4,498.
Across 78 payments — averaging $54.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akcea Therapeutics, Inc.$2K
- Abbott$594
- Novartis$318
- Alnylam Pharmaceuticals Inc.$120
- Vifor Pharma, Inc.$116
- Pfizer$112
- plus $533 from 13 others
Across 14 payments — averaging $4886.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$39K
- Merck$30K
What the payments were for
- Speaking & faculty fees$2,00047%
- Travel & lodging$2125%
- Food & beverage$1,95046%
- Education$581%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akcea Therapeutics, Inc. | 9 | $2,427 |
| Abbott | 13 | $594 |
| Novartis | 15 | $318 |
| Alnylam Pharmaceuticals Inc. | 5 | $120 |
| Vifor Pharma, Inc. | 6 | $116 |
| Pfizer | 6 | $112 |
| Impulse Dynamics (USA) Inc. | 1 | $76 |
| Boehringer Ingelheim | 4 | $74 |
| Actelion Pharmaceuticals US, Inc. | 4 | $74 |
| Amgen | 4 | $71 |
| Livanova USA, Inc. | 2 | $49 |
| Coherus Oncology, Inc. | 1 | $48 |
| Boston Scientific | 2 | $46 |
| Bayer | 1 | $20 |
| GRT US Holding, Inc. | 1 | $19 |
| Nuwellis, Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Medtronic | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEGSEDI$2,175
- CardioMEMS HF System$232
- ENTRESTO$121
How this compares
$4,220 in reported general payments places this provider in the 40th percentile of 43 advanced heart failure and transplant cardiology providers in Virginia.
See all advanced heart failure and transplant cardiology providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CamzyosMavacamten | 47 | $394,177 |
| EliquisApixaban | 184 | $210,923 |
| XareltoRivaroxaban | 43 | $57,081 |
| EntrestoSacubitril/Valsartan | 32 | $33,529 |
| FarxigaDapagliflozin Propanediol | 21 | $28,187 |
| JardianceEmpagliflozin | 14 | $12,951 |
| Ranolazine ErRanolazine | 41 | $4,817 |
| Metoprolol Succinate | 258 | $3,297 |
| Ezetimibe | 53 | $2,007 |
| Amiodarone Hcl | 55 | $2,001 |
| Midodrine Hcl | 15 | $1,470 |
| Losartan Potassium | 165 | $1,462 |
| Atorvastatin Calcium | 139 | $1,447 |
| Rosuvastatin Calcium | 79 | $1,400 |
| Potassium Chloride | 55 | $1,331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $112 | $210,923184 claims |
| NovartisEntresto | $318 | $33,52932 claims |
| AstraZenecaFarxiga | $15 | $28,18721 claims |
| Boehringer IngelheimJardiance | $74 | $12,95114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 43 advanced heart failure and transplant cardiology providers in Virginia.
Other advanced heart failure and transplant cardiology in Culpeper
- Amin YehyaNorfolk$398K
- John HerreChesapeake$270K
- Raymond BenzaNorfolk$141K
- Palak ShahFalls Church$112K
- Zackary TushakNorfolk$92K
- Shashank DesaiFalls Church$80K
- Keyur ShahRichmond,$62K
- Mirnela BykuCharlottesville$62K
- Edward SaweyRichmond$35K
- Michael FlanaganFalls Church$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.